at the end of Day One of the TROG Annual Scientific Meeting in Adelaide, South Australia.
We welcomed participation from many of our valued members, both face-to-face and via the video conference facility provided.
The nominations call for election of two Full Member Board Directors to the Trans Tasman Radiation Oncology Group Limited, ACN 132672292 (known as TROG Cancer Research) concluded on Tuesday 6th June, 2023. At the close of business on this day 6th June 2023, two nominations were received: (1) Professor Annette Haworth and (2) Associate Professor Purnima Sundaresan. The Company Secretary of TROG Cancer Research verified the nomination according to criteria outlined within the TROG Cancer Research constitution and the candidates nominations were accepted by the TROG Cancer Research Board.
As per Clause 8.3 ELECTION PROCESS, sub section (e) (i) of the constitution, the election of these two candidates will not require a TROG Cancer Research member voting process at the upcoming AGM, as in subsection (e) The Board may appoint a candidate on the appointment date without holding a ballot if: (1) The number of candidates is equal to or less than the number of vacancies,”.
Professor Annette Haworth and Associate Professor Purnima Sundaresan are current serving Full Member Directors of the TROG Cancer Research Board and their re-election was welcomed by TROG Cancer Research.
We also acknowledged that our current Board President, Prof Trevor Leong, has entered his final year of tenure and the process of nomination of President Elect has been completed as of 22nd June 2023. A single candidate nomination was received and accepted by the Board. Associate Professor Purnima Sundaresan has been duly elected to serve as President Elect until 2024 AGM.
You can now view the minutes of the 2023 AGM.
Find out about TROG’s operations and finances
Ask questions about the operations and finances of TROG
Speak about any items on the agenda
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292